Doxorubicin, a 50-year-old chemotherapy drug still in widespread use against a variety of cancers, has long been known to cause cardiotoxicity in some patients. Scientists have identified an unexpected mechanism via the enzyme Top2b that drives the drug's attack on heart muscle, providing a new approach for identifying patients who can safely tolerate doxorubicin and for developing new drugs. A team led by scientists at The University of Texas MD Anderson Cancer Center reports its findings in the journal Nature Medicine. Read more here.
Study mentioned: Zhang S, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012 Oct 28. [Epub ahead of print] PMID: 23104132
No comments:
Post a Comment